Arrowhead Pharmaceuticals posts $370.4 million net income for fiscal Q2 2025
Arrowhead Pharmaceuticals reported fiscal second-quarter 2025 results for the period ended March 31, 2025, with revenue of $542.7 million versus none a year earlier and net income attributable to the company of $370.4 million, compared with a loss of $125.3 million in the prior-year quarter. The company also said it expects to be funded into 2028 following its Sarepta Therapeutics agreement, and that its CFO, Ken Myszkowski, will retire effective May 13, 2025, succeeded by Daniel Apel.
Key points
- Revenue was $542.7 million for the quarter, compared with $0 in the year-earlier period.
- Net income attributable to Arrowhead was $370.4 million, or $2.75 per diluted share, versus a loss of $1.02 per share a year earlier.
- Research and development expenses rose to $133.1 million from $101.1 million.
- CFO Ken Myszkowski retires effective May 13, 2025; Daniel Apel succeeds him.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.